Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2003 | 12-2002 | 09-2002 | 06-2002 | 03-2002 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,150 | 1,920 | 1,270 | 780 | 960 |
| Other current assets | 90 | 70 | 50 | 90 | 100 |
| TOTAL | $2,240 | $1,990 | $1,320 | $870 | $1,060 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 120 | 100 | 90 | 90 | 90 |
| TOTAL | $120 | $100 | $90 | $90 | $90 |
| Total Assets | $2,560 | $2,280 | $1,590 | $1,150 | $1,290 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 10 | 0 | 0 | 0 | 0 |
| Accounts payable and accrued liabilities | 250 | 300 | 220 | 550 | 200 |
| Accrued Expenses | 40 | 170 | 80 | 40 | 220 |
| Other current liabilities | 0 | 170 | 0 | 0 | 150 |
| TOTAL | $310 | $660 | $430 | $710 | $780 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 100 | 0 |
| TOTAL | $N/A | $N/A | $N/A | $100 | $N/A |
| Total Liabilities | $310 | $660 | $430 | $810 | $780 |
| Shareholders' Equity | |||||
| Common Shares | 20 | 10 | 10 | 10 | 10 |
| Retained earnings | -8,770 | -7,880 | -6,710 | -6,050 | -5,110 |
| Other shareholders' equity | -40 | -150 | -190 | -60 | -80 |
| TOTAL | $2,250 | $1,610 | $1,160 | $340 | $510 |
| Total Liabilities And Equity | $2,560 | $2,270 | $1,590 | $1,150 | $1,290 |